Follicular lymphoma (FL) is the second-most common nonHodgkin's lymphoma. The disease affects the lymph nodes, and 50% of patients present with bone marrow infiltration; however, the mechanisms involved in dissemination of the disease are not yet known. We previously reported that FL cells display an overexpression of Syk, a tyrosine kinase involved in many cellular processes including cell migration. Therefore, we sought to explore its role in the invasive process. Here, we show that FL patients display higher matrix metalloproteinase (MMP)-9 and vascular endothelial growth factor (VEGF) levels than healthy donors. Moreover, using Syk small interfering RNA and the Syk inhibitor R406, we demonstrate that, in FL cells, Syk is involved in the regulation of MMP-9 and VEGF expression, and that invasion and angiogenesis is mediated through a phosphatidylinositol-3 kinase (PI3K)-mammalian target of rapamycin module. Finally, using a FL xenograft mouse model we observe that fostamatinib (R788), inhibits MMP-9 expression and angiogenesis in vivo. Altogether, this study provides strong evidence that Syk represents an encouraging therapeutic target in FL and suggests the potential use of fostamatinib as an anti-invasive and anti-angiogenic drug.
Introduction
Follicular lymphoma (FL) is the second-most frequent type of non-Hodgkin's malignant lymphoma. Despite significant improvement in therapy, mostly because of the combination of chemotherapy and rituximab, without stem cell transplantation this disease is still considered non-curable. Therefore, there is a need to identify cellular targets in order to define new pharmacological approaches. To this end, we have previously investigated the signaling components that converge to activate the mammalian target of rapamycin (mTOR) in FL cells. 1, 2 We focused on the tyrosine kinase Syk that, through mTOR, has a key role in the proliferation and survival of FL cells. 1 Syk is a 72-kDa non-receptor protein tyrosine kinase that contains two NH2-terminal SH2 domains and a COOHterminal kinase domain. Syk is abundant in B lymphocytes and expressed at lower levels in immature T cells, mast cells and platelets. In addition, Syk has been detected in fibroblasts, epithelial cells and breast tissues. Syk participates in the transduction of signals initiated by the ligation of multiple hematopoietic cell surface receptors, which include antigen receptors, integrins, collagen receptors and the Fc receptors (for reviews see Tauzin et al.
3
; Riccaboni et al. 4 ; Mocsai et al. 5 ). In B cells, Syk is a crucial player in the B-cell receptor (BCR)-activating platform. Indeed, Syk-deficient B cells are largely non-responsive to BCR aggregation. 6 Pathways leading to Syk activation are initiated by phosphorylation of immunoreceptor tyrosine-based activation motifs, located on the cytoplasmic domains of immunoglobulins a and b. Activated Syk couples the BCR to multiple downstream signaling pathways, including calcium mobilization from intracellular stores and activation of phosphatidylinositol-3 kinase (PI3K) or phospholipase Cg. This orchestrates various cellular responses, such as proliferation, differentiation, survival and phagocytosis (for reviews see Riccaboni et al. 4 ; Geahlen 6 ). In addition to these important roles, Syk has also been implicated in cell motility. Syk has been reported as critical for integrin-mediated polarization and migration of polymorphonuclear neutrophils, 7 as well as for endothelial and B-cell migration. 8, 9 A role for Syk has also been proposed in migratory and invasive processes in pathological contexts such as malignancies but, depending on the cellular model, Syk can act as a tumor suppressor or an oncogenic protein. Indeed, in various cancers, such as breast cancer, gastric cancer or melanoma, loss of Syk expression correlates with tumor progression, metastasis formation and poor prognosis. [10] [11] [12] A negative role in motility and invasion of a breast cancer model has also been described. 13 Conversely, in nasopharyngeal carcinoma cells 14 and squamous-cell carcinoma of the head and the neck, 15 high Syk expression correlated to a poor survival rate. In these malignancies, Syk is thought to promote a migratory behavior and invasiveness, leading to tumor progression and metastasis; however, the mechanisms underlying this process are not yet clear. Previous studies have proposed that Syk participates in the regulation of expression of matrix metalloproteinases (MMPs), key proteases involved in the invasive process. In myeloid cells, migration toward inflammatory sites is induced by activation of a Syk/PI3K/MMP-2 and MMP-9 pathway; 16 and an inverse relationship between Syk, MMP-9 and tumor progression has been proposed in breast cancer. 17 MMPs represent a large family of enzymes that can degrade most extracellular matrix components, acting both in physiological and pathological events, such as development, tissue repair, wound healing and cancer progression. They have been implicated in the field of tumor growth and metastasis in promotion of the release of matrix-bound components such as growth factors. 18, 19 Within the MMP family, the gelatinases MMP-2 and -9, with substrate specificity for denatured collagens (gelatin) and type IV collagen localized in the basement membrane, are involved in the progression and invasion of solid tumors. Their expression has been linked to invasive behavior, and high levels of these two gelatinases have also been associated with active neovascularization and angiogenesis. 18, 20 Vascular endothelial growth factor (VEGF) is one of the major molecules involved in both physiological and pathological angiogenesis, such as that associated with tumor growth. 21 This factor is produced by a wide range of tumor cells and some tumor-associated stromal cells. Angiogenesis appears to be of particular importance in the physiopathology of lymphomas, as disease progression was found to correlate with increased angiogenic activity, 22 and inhibition of VEGF receptor signaling decreased the tumor burden in lymphoma xenografts. 23 Clinical studies have revealed that increased MMP-9 expression is associated with a higher metastatic rate and aggressiveness, and correlates with poor prognosis in a wide range of solid tumors, including breast, lung and cutaneous melanoma. 18 The expression levels of VEGF mRNA and protein also correlate with malignant progression and poor prognosis in nonhematopoietic malignancies. 24, 25 In non-Hodgkin's lymphomas (NHLs), a high expression of MMP-9 has been correlated with tumor grade 26, 27 and high VEGF serum levels have been linked to poor clinical outcome. 28 However, NHLs correspond to a heterogeneous group of malignancies with variable clinical course and these studies did not focus on FL. In fact, to our knowledge no study has ever investigated the mechanisms involved in FL migration. This is of particular pertinence as, based on bone marrow lymphomatous infiltration, 50% of FL patients are thought to display a disseminated disease at diagnosis. Thus, this study sought to determine whether and how Syk regulates MMP-9 and VEGF expression in vitro and in vivo, and aimed to highlight the role of this tyrosine kinase in angiogenesis and the invasive process.
Materials and methods

Cell lines and reagents
RL, Oci-Ly8 and WSU-FSCCL are transformed human FL cell lines carrying the t(14;18) translocation. They were obtained from the American Type Cell Collection (Rockville, MD, USA), a kind gift from Professor Delsol (CRCT INSERM U1037) and Deutsche Sammlung von Mikroorganismen und Zellkulturen (Braunschweig, Germany), respectively. Cells were cultured at 37 1C in 5% CO 2 in RPMI supplemented with 10% fetal calf serum, glutamine (2 mM), streptomycin (10 mg/ml) and penicillin (200 U/ml; Invitrogen, Cergy Pontoise, France).
The Syk inhibitor R406 and its clinically used oral formulation R788 (fostamatinib disodium) were provided by Yasumichi Hitoshi (Rigel Pharmaceuticals, South San Francisco, CA, USA). R406 was dissolved in dimethyl sulfoxide at a concentration of 10 mM. R788 was dissolved in 0.1% carboxymethylcellulose, 0.1% methylparaben, 0.02% propylparaben (Camida, Tipperary, Ireland) at a final concentration of 4 mg/ml.
LY294002 was purchased from Sigma-Aldrich (St Quentin Fallavier, France). GDC-0941, a PI3K inhibitor, was provided by Synkinase (Shanghai, China). The MMP-2/MMP-9 inhibitor II, BiPS, was obtained from Calbiochem (VWR, Neuilly sur Marne, France).
Dimethyl sulfoxide was used as the negative control for R406, LY294002, GDC-0941 and BiPS treatments.
FL serum collection
Peripheral blood samples were collected from 16 
ÀDDCt
, where DDCt is the difference between the DCt of the sample and the DCt of the reference dimethyl sulfoxide control. DCt is the difference between the Ct of the target gene and the GAPDH gene.
Western blotting
Analyses were performed as previously described. 1, 2 The different antibodies used for western blotting were: anti-phospho-p70S6K (Thr389), anti-phospho-Akt (Ser473), anti-Syk (all from Cell Signaling Technology, St Quentin Yvelines, France), anti-MMP-9 (Millipore, Molsheim, France) and anti-b-actin (Lab Vision Corporation, Francheville, France). Horseradish peroxidase-conjugated secondary antibodies against rabbit or mouse immunoglobulins were from Jackson Immunoresearch Laboratories (Immunotech, Marseille, France).
Secreted MMP-9, MMP-2 and VEGF quantification MMP-9, MMP-2 and VEGF levels were measured in sera from FL patients and healthy donors or in supernatants obtained from RL cells. Secreted MMP-9, MMP-2 or VEGF levels were quantified by enzyme-linked immunosorbent assays according to the manufacturer's recommendations (VWR).
Three-dimensional Matrigel invasion assay
RL, Oci-Ly8 and WSU-FSCCL cells, pretreated or not with R406 for 48 h, were stained with 2 mM of the fluorescent dye CellTracker Orange CMTMR (Invitrogen) for 1 h. In the siRNA experiment, RL cells were transfected with MMP-9 or control siRNA and, 24 h after the second round of transfection, cells were stained as described above with CMTMR. Then, after two washes in phosphate-buffered saline, 0.3 Â 10 6 cells were seeded in complete medium, allowed to attach to Lab-Tek chambers (Nunc, Rochester, NY, USA) and treated or not with 2.5 mM BiPS for 2 h. The medium was then taken off and cells were overlaid with 5 mg/ml Matrigel basement membrane matrix (BD Biosciences, Le pont De claix, France). The different inhibitors or vehicle used were added to the matrix at the same concentration. The matrix was allowed to gel for 1 h at 37 1C before the addition of medium with 15% fetal calf serum. After 24 h, the invasive capacity of cells into the three-dimensional Matrigel matrix was analyzed by confocal microscopy with a Carl Zeiss LSM 510 confocal microscope (Jena, Germany). Optical Z-stacks were taken every 5 mm, starting at the bottom of the dish and extending at least 100 mm into the gel, at Â 20 magnification. Three-dimensional imaging and cell quantification were performed using Imaris 5.5 software (Bitplane AG, Zurich, Switzerland). The invasive capacity of the cells was calculated from the number of cells above 20 mm divided by the total number of cells in the Z-section. Data arose from the analysis of X300 cells for each condition.
PI3K activity
RL cells (5 Â 10 6 ) were pelleted and lysed with 500 ml lysis buffer (40 mM Tris, pH 7.4, 100 mM NaCl, 100 mM NaF, 1 mM NaVO 3 , 40 mM Na 4 P 2 O 7 , 20mM aprotinin, 20 mM leupeptin, 1 mM phenylmethanesulfonylfluoride, 1% Triton X-100 and 10 mM EDTA). After a preclearing step with 20 ml protein A sepharose (Amersham Biosciences, Orsay, France), protein extracts (300-500 mg) were incubated with 5 mg anti-p85 PI3K antibody (Cell Signaling Technology) and 20 ml protein A sepharose overnight at 4 1C. Immune complexes were washed once with 500 ml lysis buffer and twice with 500 ml wash buffer (10 mM Tris, pH 7.4, 100 mM NaCl, 100 mM Na 3 VO 4 , 1 mM phenylmethanesulfonylfluoride, 20 mM aprotinin and 20 mM leupeptin).
PI3K activity was measured in a final volume of 60 ml containing 100 mM Tris-HCl, pH 7.4, 3 mM Dithiothréitol, 200 mM NaCl, 1 mM EDTA, 10 mM MgCl 2 , 100 mM ATP, 10 mCi [g 32 P]ATP, exogenous lipid vesicles (10 ml phosphatidylinositol 4,5-bisphosphate plus 20 ml phosphatidylserine, prepared by sonication in 100 mM Tris-HCl, pH 7.4) and p85 immunoprecipitates. After 10 min at 37 1C, reactions were stopped by adding 1 N HCl, followed by a mixture of chloroform/methanol (vol/vol). Lipids were extracted and separated by thin-layer chromatography (Merck, West Point, PA, USA) using chloroform/methanol/ammonia (9:7:2 vol/vol). Radioactive spots corresponding to 32 P-PI 3 P were visualized by autoradiography, then scraped and quantified by liquid scintillation spectrometry.
FL xenograft murine model
Ten million RL cells (resuspended in 300 ml phosphate-buffered saline) were subcutaneously injected into the right flank of severe combined immunodeficiency-Beige mice, according to the INSERM Animal Care and Use Committee-approved protocol. When tumor volumes (TVs) reached 100 mm 3 , mice were divided into experimental groups of 8-10 animals. The treated group consisted of animals injected intraperitoneally with 80 mg/kg R788 once daily. For the control group, the vehicle was injected with the same schedule and route of administration. Tumor burden was measured twice a week with a caliper, and TV was calculated using the formula (TV ¼ (length Â width 2 )/2). Animals were killed when the TV of the control group reached 2500/3000 mm 3 . Tumors were harvested and submitted to immunohistochemistry analyses.
Immunohistochemistry
Formalin-fixed, paraffin-embedded tissue sections from FL-affected lymph nodes (Service d'Anatomopathologie, CHU Purpan, Toulouse, France) or xenograft FL tumors were mounted on superfrost-plus slides. Before immunodetection, specimens were deparaffinized and rehydrated. Endogenous peroxidase and biotin activities were blocked with specific reagents. Antigen retrieval of dewaxed sections was performed by heat treatment in 10 mM citrate buffer at pH 6.
Sections were incubated with anti-MMP-9 (clone 56-2A4, 1:500, 1 h at room temperature; Millipore SAS), anti-SYK (clone 4D10, 1:50, 1 h at room temperature; Thermo Fisher Scientific, Illkirch, France), rat monoclonal anti-CD34 (clone MEC14.7, 1:400, 3 h at room temperature; AbD Serotec, Oxford, UK), rabbit polyclonal anti-VEGF (SC-152, 1:100, 1 h at room temperature; Santa Cruz Biotechnology, Le Perray en Yvelines, France) and anti-phospho-p70S6K (Thr421:Ser424) (no. 9204, 1:50, overnight/4 1C; Cell Signaling Technology).
After incubation with the aforementioned antibodies, sections were incubated with biotin-conjugated polyclonal anti-mouse, anti-rat or anti-rabbit immunoglobulin antibodies, followed by the streptavidin-biotin-peroxidase complex (ABC method; Vectastain ABC kit, Vector Laboratories, CA, USA) and then were counter-stained with hematoxylin. Negative controls were incubated in buffered solution without primary antibody.
MMP-9, SYK, VEGF, CD34 and phospho-p70S6K were detected with a Leica DMR microscope and IM50 software (Rueil-Malmaison, France).
Evaluation of microvessel density
Microvessel density (MVD) of tumor tissues from vehicle-or R788-treated animals were evaluated, after immunohistochemical staining with antibody against mouse CD34, at high power field of Â 100. The CD34-stained cells were quantified using NIS-Elements AR software (Nikon, Champigny sur Marne, France). MVD is expressed as the mean of CD34-positive cell percentage in at least four fields for each tumor sample.
Statistics
Data shown represent means þ s.d. Results were analyzed using Student's t-test or one-way analysis of variance test to assess statistical significance. Statistical differences are presented at probability levels of Po0.05 (which was considered statistically significant) and Po0.005.
Results
Syk regulates MMP-9 expression and promotes invasiveness of FL cells
The role of Syk in MMP-9 expression was examined first by treating RL cells, an FL cell line, with the Syk inhibitor R406.
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As shown in Figure 1 , pharmacological Syk inhibition induced a potent decrease in MMP-9 mRNA expression. Quantitative PCR analysis revealed that MMP-9 mRNA levels were 2.8-and 4.3-fold lower at 24 and 48 h after R406 treatment, respectively ( Figure 1a ). To confirm that the decrease in MMP-9 expression was mediated by Syk, we used an siRNA approach to specifically knockdown the tyrosine kinase expression (Figure 1b insert) . As expected, a 3.4-fold reduction of MMP-9 expression was measured after Syk depletion (Figure 1b) . The siRNA experiments were also carried out using Oci-Ly8 and WSU-FSCCL cells, two other FL cell lines (Supplementary Figures S1A and S2A, respectively) , and confirm a role for Syk in MMP-9 expression in FL cells.
Total intracellular MMP-9 protein levels were also decreased after Syk inhibition either by R406 treatment or siRNA transfection as attested by western blot analysis (Figure 1c) . Therefore, we investigated whether the secreted levels of MMP-9 were also affected by Syk inhibition. As shown in Figure 1d , R406 treatment significantly inhibited MMP-9 secretion into the cell supernatant (2.3-fold lower at 48 h after treatment).
We have previously characterized the Syk-mTOR module as overactivated in FL cells.
1 Consistent with the above data, treatment with rapamycin, an mTOR inhibitor, gave the same results (data not shown), supporting the idea that MMP-9 expression is regulated by Syk-mTOR.
To evaluate whether Syk can control FL cell behavior, in particular their invasive properties, we performed an invasion assay in a dense three-dimensional Matrigel matrix, which mimics the basement membrane. Invasion was promoted using 15% fetal calf serum as a chemoattractant gradient and was quantified by confocal microscopy. As observed in Figure 2a These results were confirmed using siRNA (Supplementary Figure S3) , demonstrating that MMP-9 also contributes to the invasive properties of FL cells.
These results suggest that the Syk-mTOR pathway is involved in the invasive behavior of FL through regulation of MMP-9 expression.
The PI3K/Akt/mTOR pathway is involved in Syk-induced MMP-9 expression
In B cells, it is well-established that Syk stimulates PI3K, which is involved in signaling pathways downstream of the BCR. 29 Thus, we explored the role of Syk as an upstream regulator of PI3K in FL cells. As shown in Figure 3a , Syk inhibition by R406 treatment or by siRNA transfection strongly affected the activation of Akt and p70S6K, as revealed by the dramatic decrease in Akt phosphorylation on Ser473 and p70S6K phosphorylation on the Thr389 activation site. We found these decreased activation rates to be linked to inhibition of PI3K activity (Figure 3b) . Similar results were Figure S2B) cell lines. The role of PI3K in mTOR-induced MMP-9 expression was confirmed by treating the cells with the classical PI3K inhibitor LY294002. As shown in Figure 3c , LY294002 treatment strongly inhibited mTOR activation (Figure 3c1 ) and resulted in decreased levels of both MMP-9 mRNA and protein (Figures 3c2 and c3,  respectively) . These results were confirmed in the three FL cell lines using GDC-0941, a potent class I PI3K inhibitor (Supplementary Figure S4) . 30, 31 Together, these results suggest that PI3K is a key component of the Syk-mTOR-MMP-9 pathway in FL cells.
MMP-9 is overexpressed in FL patients
Elevated MMP-9 expression and serum levels have been described in patients suffering from NHL. 26 , 27 We therefore sought to determine whether this was also the case in FL samples by quantifying MMP-9 serum levels using enzymelinked immunosorbent assay. We observed that sera from FL patients displayed a 3.3-fold increase in secreted MMP-9 levels when compared with healthy donors (789.7±193.2 vs 240.8 ± 52.2 ng/ml, Po0.005; Figure 4a ). MMP-2, another gelatinase, has been detected in NHLs, where its expression correlates with tumor grade. 32 However, we found no statistical difference between MMP-2 concentration in sera from healthy donors compared with FL patients (523.56 ± 65 vs 545.45 ± 76.2 ng/ml, P ¼ 0.44). This is consistent with results obtained by other groups. 26, 33 We also analyzed MMP-9 expression by immunohistochemistry on biopsy sections isolated from FL-affected lymph nodes. As shown in Figure 4b , cells derived from FL patients displayed an intense MMP-9 staining in the cytosol. These specimens also exhibited high Syk staining and a strong * * * * * * * * * * Syk impacts on follicular lymphoma cell invasion S Fruchon et al nuclear and cytoplasmic labeling, with an antibody directed against the phosphorylated form of p70S6K, which mirrors mTOR activation. 1 To determine whether MMP-9 staining correlates with FL aggressiveness, we analyzed 12 FL patients. Staining intensity was classified as either bright (group A), weak (group B) and negative (group C) to indicate the expression level of MMP-9 in the 12 different FL biopsies (Table 1 and illustrated in Supplementary Figure S5) . Although the small size of the cohort does not allow firm conclusions to be drawn (Table 1) , we observed that patients in group A present a shorter treatmentfree survival than in groups B and C (18 ± 6 months for group A vs 68±22 and 48 months for B and C, respectively). This is not linked to the treatment received, as patients who received highly active rituximab-chemotherapy had disappointing results. In these 12 patients, no correlation was found between MMP-9 staining and Ann-Arbor stage, prognostic index (Follicular Lymphoma International Prognostic Index (FLIPI)) or bulky disease (based on Groupe d'Etude des Lymphomes Folliculaires score). These preliminary data point to a putative prognostic role for MMP-9 staining, especially for treatment-free survival.
Together, these results show that FL patients exhibit a high level of MMP-9 expression and secretion.
VEGF is overexpressed in FL patients and is regulated by the Syk-mTOR pathway
It is now well-established that, besides its key role in invasiveness, MMP-9 is a potent regulator of angiogenesis. 20 Angiogenesis is increased in hematological malignancies Syk impacts on follicular lymphoma cell invasion S Fruchon et al including NHLs, and elevated VEGF serum levels have been associated with poor prognosis. 34 Thus, we sought to determine the level of secreted VEGF in FL serum samples using enzymelinked immunosorbent assays. We observed a higher level of secreted VEGF in FL serum samples when compared with healthy donors (482.1±274.2 vs 295.5±142.9 pg/ml, Po0.05) (Figure 5a) .
We also analyzed VEGF expression by immunohistochemistry on biopsy sections isolated from FL-affected lymph nodes (Figure 5b) . In most cases analyzed, we observed that cells derived from FL patients display an intense VEGF staining.
As mTOR is involved in VEGF expression, 35 we wondered whether Syk could act as an upstream regulator of VEGF. Using both an siRNA strategy and pharmacological treatment, we found that Syk inhibition induced a decrease in VEGF mRNA expression levels (Figures 5c1 and c2, respectively) and a potent reduction of secreted VEGF, as shown in Figures  5d1 and d2 . These data were confirmed in Oci-Ly8 and WSU-FSCCL cell lines (Supplementary Figure S6) . Similar results were obtained after rapamycin treatment (data not shown), supporting the role for the Syk-mTOR module in this process. Together, these results show that the Syk-mTOR pathway is involved in VEGF expression in FL cells.
Decreased MMP-9 expression and angiogenesis following Syk inhibition in an FL xenograft model
To investigate the role of Syk in vivo, we subcutaneously injected RL cells into severe combined immunodeficiencyBeige mice. When the TV reached B100 mm 3 , mice were intraperitoneally injected with control (vehicle) or R788, a clinically used oral formulation of R406, at a dose of 80 mg/kg once daily. We found that R788 inhibited tumor growth (Figure 6a ), as has been described for other hematological malignancies. 36 At the end of the treatment, the mean TV of the R788-treated animals was nearly threefold lower when compared with that of the control group (2918±909 vs 987 ± 422 mm 3 , Po0.001). We also performed immunohistochemical labeling on RL-derived tumors (Figure 6b ). This showed that Syk inhibition decreased MMP-9 expression, thus confirming our results obtained in vitro.
We then assessed the in vivo role of Syk in angiogenesis using immunohistochemistry and microscopic estimation of MVD on tumor tissues stained for endothelial cell-surface marker (CD34). Through this method we evaluated intratumoral MVD and observed a robust reduction in tumor vasculature in the R788-treated group (Figure 6b ). The mean MVD was clearly reduced in R788-treated tumors as attested by the fivefold fewer rate of CD34-positive cells when compared with that of vehicletreated animals (Figure 6c ). These results strongly suggest that Syk is a key regulator of angiogenesis.
These results show that Syk regulates MMP-9 expression and angiogenesis in vivo.
Discussion
Syk has been described to have a role in both normal and tumoral cell migration and invasion. 7, 8, 10, 14, 15 Recently, migration of myeloid cells was correlated with Syk-dependant MMP expression. 16 In this study, we show for the first time that Syk can induce FL cell invasion by increasing MMP-9 synthesis both in vitro and in vivo. Our results were obtained in three different FL cell lines from patients presenting with the disease at various stages and by the use of the Syk inhibitor R406. It must be noted that this compound also affects other kinases closely related to Syk, such as Lyn, Flt3 or Lck. 37 However, the concentrations required to inhibit these kinases are higher than those needed to inhibit Syk. The similarity of the results obtained in our study with Syk siRNA knockdown experiments supports the notion that Syk is the main kinase involved in the regulation of MMP-9 expression in our FL cellular models. Several studies have reported elevated MMP-9 expression in NHLs 26, 27, 32 and, in some studies, a correlation with poor prognosis. 27, 38 In our study, we found that MMP-9 expression in vivo was found to be Syk dependant, and that FL patients displayed a higher expression of MMP-9 than healthy donors. This suggests that R788 could represent a novel anti-metastatic drug. The role of Syk as a target for anti-migratory therapy has also been suggested by Quiroga et al. 39 who demonstrated that, in vitro, Syk positively regulates B-chronic lymphocytic leukemia migration.
We also show that, in FL cells, Syk activates PI3K, a kinase involved in MMP-9 expression in various cellular models. 40, 41 The fact that Syk could act upstream of PI3K was expected, as it is well-described downstream of BCR activation 29 but also surprising as we have previously found that piceatannol, a Syk pharmacological inhibitor, did not inhibit PI3K activity or Akt phosphorylation. 1 In the present study, we observed that R406 treatment and Syk siRNA transfection inhibited PI3K activity as measured by kinase assay and western blot analysis of two PI3K targets, Akt and p70S6K. Therefore, this suggests that piceatannol interferes with pathways other than Syk. The results presented herein provide strong evidence that Syk activates Syk impacts on follicular lymphoma cell invasion S Fruchon et al PI3K, as has previously been described in other cellular contexts. 29, 42 Moreover, we found that rapamycin inhibits MMP-9 synthesis, supporting a role for mTOR in cell invasion. 43 This is of particular interest because many studies have shown the importance of the PI3K/Akt/mTOR pathway in the biology of malignant cells, 44, 45 providing a strong rationale for the development of inhibitors that suppress the PI3K/Akt/mTOR pathway as a therapy for hematological malignancies. [46] [47] [48] [49] [50] It would be very interesting to test the combination of a Syk inhibitor with PI3K or mTOR inhibitors such as GDC-0941 or AZD8055, respectively, which have demonstrated beneficial effects in a spontaneous B-cell FL model. 51 Syk is also known to activate downstream targets involved in cell migration, such as FAK, PYK2 and ezrin. 5, 52, 53 FAK and PYK2 kinases are upstream of PI3K/Akt 54, 55 and therefore potentially connect Syk and PI3K-mTOR; however, we were unable to establish a role for them in MMP-9 expression and FL cell migration using siRNA or pharmacological inhibitors. One could speculate that, in FL cells, Syk directly activates PI3K, leading to mTOR activation, MMP-9 expression and cell migration, as a direct interaction between Syk and the p85-regulatory subunit of PI3K has been described. 56 In this study, we also provide evidence that, in FL cells, the Syk-mTOR pathway regulates VEGF expression. This is the most potent inducer of tumor angiogenesis 21 and, to our knowledge, this is the first work showing that in hematological malignancies Syk positively regulates VEGF expression. Moreover, our study highlights a new therapeutic strategy in the use of R788 as an anti-angiogenic drug in FL cells as Syk inhibition strongly induced the angiogenic process in our xenograft model. When considering the mechanism of Syk-mediated regulation of VEGF expression, there are two hypotheses. First, that Syk directly regulates VEGF at a transcriptional level, as we observed that Syk and mTOR inhibition strongly reduced VEGF at the mRNA level. This could occur through the activity of specific transcription factors such as hypoxia-inducible factor-1a in response to Akt-mTOR signaling, as has been described in a human ovarian cancer model, 57 or through Sp1, another transcription factor known to regulate VEGF expression 58 and which could interact with Syk. 59 The second hypothesis is based on several lines of evidence supporting a role for MMP-9 in the angiogenic process. 20 Moreover, some studies highlight the fact that VEGF and MMP-2/-9 regulate each other, thereby contributing to tumor progression. In a recent study, Chetty et al. 60 demonstrated that MMP-2 regulates angiogenesis in lung cancer cells through VEGF transcriptional expression in a PI3K/Aktdependant manner. The regulation of VEGF expression by MMP-2 seems to be induced via hypoxia-inducible factor-1a, a target of the PI3K/AKT pathway. A complex interplay between VEGF and expression of MMPs has also been described in ovarian cancer, 61 but further investigation is needed to better understand this relationship. Whatever the mechanism by which the Syk-mTOR pathway regulates VEGF, our study clearly shows that Syk affects VEGF production. This is important to consider as it has been described that FL patients display a high level of VEGF and this is associated with a poorer overall survival. 62 In the last few years, Syk has become a very promising therapeutic target in hematological malignancies. Indeed, several lines of evidence support the idea that this tyrosine kinase has a central role in cell survival, proliferation and migration. 6 Moreover, we and others have observed overactivation and/or overexpression of Syk in different B lymphomas, such as FL, mantle cell lymphoma, diffuse large B-cell lymphoma, Burkitt and B-chronic lymphocytic leukemia. 1 Using the novel Syk inhibitor developed by Rigel Pharmaceuticals (fostamatinib), numerous studies have demonstrated that Syk inhibition is able to induce apoptosis in diffuse large B-cell lymphoma 63 and B-chronic lymphocytic leukemia 64 by affecting the activation of prosurvival signals (Akt and Mcl-1). For our part, we have shown that Syk controls mTOR-dependant FL cell survival. 1 The key role of Syk has also been demonstrated by in vivo studies: using a mouse model, Young et al. 36 revealed that R788 (fostamatinib) was able to reduce the tumor burden and increase the mice survival rates. Together with these studies, our results demonstrate that Syk represents a therapeutic target, supporting the use of fostamatinib in NHL patients. Recently, Friedberg et al. 65 published the results of the phase I/II clinical trial with fostamatinib in relapsed and refractory NHL and B-chronic lymphocytic leukemia. Further investigation is necessary to determine whether in these patients, fostamatinib may regulate MMP-9 and VEGF expression and/or secretion.
Although further investigation is necessary, our study provides encouraging possibilities for the use of fostamatinib as an anti-lymphomatous drug for FL treatment. This is interesting as emerging evidence suggests that angiogenesis is highly relevant to lymphomas and that angiogenesis is associated with disease progression. 22 Moreover, one could speculate on new therapeutic strategies with the use of fostamatinib associated with rituximab or mTOR inhibitors, two classical drugs used in the treatment of NHLs. 46 
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